臨床ガイドラインは継続的な進行中の作業：科学の速度で前進する

“The findings demonstrate that lower, more aggressive lowering of LDL-C with use of evolocumab improves outcomes in a high-risk primary prevention population and likely endorses early clinical adoption of lower LDL-C thresholds in patients like those in the VESALIUS-CV cohort.”